MedTrace Logo

Allergic Rhinitis Changes the Sinus Microbiome

NCT01852513 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-10-09

Study results available
· View outcomes & findings →

Summary

The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

QNASL

DRUG

Placebo nasal spray

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jayant Pinto, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-11-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01852513 on ClinicalTrials.gov